Table: Towa Pharmaceutical - 6-MTH group results
Nov 12 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2018 Sep 30, 2017 Mar 31, 2019
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 49.14 44.70 102.80
(+9.9 pct) (+10.3 pct) (+10.0 pct)
Operating 5.92 5.08 12.00
(+16.7 pct) (+118.6 pct) (+3.1 pct)
Recurring 8.37 6.06 12.20
(+38.2 pct) (+4.1 pct)
Net 6.18 4.30 8.95
(+43.5 pct) (+37.8 pct)
EPS 376.59 yen 262.37 yen 545.63 yen
EPS Diluted 348.34 yen 242.62 yen
Ann Div 95.00 yen 95.00 yen
-Q2 div 47.50 yen 47.50 yen
-Q4 div 47.50 yen 47.50 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results